Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 6.28
PACB's Cash-to-Debt is ranked higher than
59% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. PACB: 6.28 )
Ranked among companies with meaningful Cash-to-Debt only.
PACB' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.41  Med: 7.75 Max: No Debt
Current: 6.28
Equity-to-Asset 0.64
PACB's Equity-to-Asset is ranked higher than
57% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. PACB: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
PACB' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.1  Med: 0.64 Max: 0.92
Current: 0.64
-2.1
0.92
Debt-to-Equity 0.13
PACB's Debt-to-Equity is ranked higher than
72% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. PACB: 0.13 )
Ranked among companies with meaningful Debt-to-Equity only.
PACB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01  Med: 0.15 Max: 0.43
Current: 0.13
-0.01
0.43
Debt-to-EBITDA -0.17
PACB's Debt-to-EBITDA is ranked lower than
99.99% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. PACB: -0.17 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PACB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.6  Med: -0.11 Max: -0.02
Current: -0.17
-0.6
-0.02
Piotroski F-Score: 2
Altman Z-Score: -4.53
Beneish M-Score: -3.57
WACC vs ROIC
18.38%
-305.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -92.44
PACB's Operating Margin % is ranked lower than
72% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PACB: -92.44 )
Ranked among companies with meaningful Operating Margin % only.
PACB' s Operating Margin % Range Over the Past 10 Years
Min: -65237.04  Med: -324.12 Max: -31.4
Current: -92.44
-65237.04
-31.4
Net Margin % -95.97
PACB's Net Margin % is ranked lower than
73% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. PACB: -95.97 )
Ranked among companies with meaningful Net Margin % only.
PACB' s Net Margin % Range Over the Past 10 Years
Min: -64965.19  Med: -323.03 Max: -34.16
Current: -95.97
-64965.19
-34.16
ROE % -96.27
PACB's ROE % is ranked lower than
83% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. PACB: -96.27 )
Ranked among companies with meaningful ROE % only.
PACB' s ROE % Range Over the Past 10 Years
Min: -272.85  Med: -88.81 Max: -46.42
Current: -96.27
-272.85
-46.42
ROA % -59.52
PACB's ROA % is ranked lower than
76% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. PACB: -59.52 )
Ranked among companies with meaningful ROA % only.
PACB' s ROA % Range Over the Past 10 Years
Min: -81.89  Med: -54.29 Max: -24.81
Current: -59.52
-81.89
-24.81
ROC (Joel Greenblatt) % -273.81
PACB's ROC (Joel Greenblatt) % is ranked lower than
73% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. PACB: -273.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PACB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1441.77  Med: -651.94 Max: -273.81
Current: -273.81
-1441.77
-273.81
3-Year Revenue Growth Rate 31.40
PACB's 3-Year Revenue Growth Rate is ranked higher than
88% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. PACB: 31.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PACB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 38.8
Current: 31.4
0
38.8
3-Year EBITDA Growth Rate -12.70
PACB's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. PACB: -12.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PACB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -48.35 Max: -12.7
Current: -12.7
3-Year EPS without NRI Growth Rate -13.00
PACB's 3-Year EPS without NRI Growth Rate is ranked lower than
65% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. PACB: -13.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PACB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -46.2 Max: -13
Current: -13
GuruFocus has detected 3 Warning Signs with Pacific Biosciences of California Inc PACB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PACB's 30-Y Financials

Financials (Next Earnings Date: 2018-02-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

PACB Guru Trades in Q4 2016

Paul Tudor Jones 78,879 sh (New)
Murray Stahl 12,000 sh (unchged)
Jim Simons Sold Out
Lee Ainslie 9,073,874 sh (-0.24%)
» More
Q1 2017

PACB Guru Trades in Q1 2017

Steven Cohen 1,279,200 sh (New)
Lee Ainslie 9,073,874 sh (unchged)
Murray Stahl 12,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2017

PACB Guru Trades in Q2 2017

Lee Ainslie 10,603,944 sh (+16.86%)
Murray Stahl 12,000 sh (unchged)
Steven Cohen Sold Out
» More
Q3 2017

PACB Guru Trades in Q3 2017

George Soros 670,400 sh (New)
Murray Stahl 12,000 sh (unchged)
Lee Ainslie 10,603,944 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PACB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-09-30 New Buy0.11%$3.18 - $5.57 $ 3.06-28%670,400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NYSE:ENZ, NAS:RDNT, NYSE:NVTA, OSTO:CEVI, NSE:THYROCARE, NAS:OXFD, LSE:IDHC, NAS:SRDX, NYSE:ARA, NAS:NTRA, SHSE:603716, BSP:AALR3, AMEX:SENS, NAS:VIVO, XBRU:BCART, NAS:NEO, OSTO:SECT B, SZSE:300639, NAS:HSKA, TSE:2309 » details
Traded in other countries:P09.Germany,
Headquarter Location:USA
Pacific Biosciences of California Inc is a biotechnology company. It is engaged in design, development and manufacture of sequencing system to help scientists resolve genetically complex problems.

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of innovative tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Pacific Biosciences' sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Guru Investment Theses on Pacific Biosciences of California Inc

Meridian Funds Comments on Pacific Biosciences of California Inc. - Mar 08, 2016

Pacific Biosciences of California Inc. (NASDAQ:PACB) is a leader in the field of next-generation gene sequencing technology. In October, the company unveiled the Sequel™ System, a gene-sequencing platform that is smaller and less expensive than the Pacific Bioscience’s former gene sequencer. This groundbreaking technology enables longer and more accurate reads of genomes, and is the result of collaboration with Roche, a health care company with interests in human in vitro diagnostics. Late in the period, Pacific Biosciences received a $20 million milestone payment from Roche for completing the project. We believe this new platform will enable the company to penetrate a larger portion of the broader sequencing market.







From the Meridian Small Cap Growth Fund fourth quarter commentary.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
PB Ratio 3.50
PACB's PB Ratio is ranked lower than
61% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. PACB: 3.50 )
Ranked among companies with meaningful PB Ratio only.
PACB' s PB Ratio Range Over the Past 10 Years
Min: 0.52  Med: 4.4 Max: 19.08
Current: 3.5
0.52
19.08
PS Ratio 3.20
PACB's PS Ratio is ranked lower than
62% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. PACB: 3.20 )
Ranked among companies with meaningful PS Ratio only.
PACB' s PS Ratio Range Over the Past 10 Years
Min: 2  Med: 7.01 Max: 28.58
Current: 3.2
2
28.58
EV-to-EBIT -3.26
PACB's EV-to-EBIT is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. PACB: -3.26 )
Ranked among companies with meaningful EV-to-EBIT only.
PACB' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.7  Med: -3.8 Max: 0.5
Current: -3.26
-33.7
0.5
EV-to-EBITDA -3.56
PACB's EV-to-EBITDA is ranked lower than
99.99% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. PACB: -3.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
PACB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.7  Med: -4.05 Max: 0.6
Current: -3.56
-38.7
0.6
EV-to-Revenue 3.01
PACB's EV-to-Revenue is ranked lower than
60% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. PACB: 3.01 )
Ranked among companies with meaningful EV-to-Revenue only.
PACB' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.7  Med: 5.6 Max: 378.4
Current: 3.01
-2.7
378.4
Current Ratio 3.75
PACB's Current Ratio is ranked higher than
67% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. PACB: 3.75 )
Ranked among companies with meaningful Current Ratio only.
PACB' s Current Ratio Range Over the Past 10 Years
Min: 2.22  Med: 5.74 Max: 22.74
Current: 3.75
2.22
22.74
Quick Ratio 3.15
PACB's Quick Ratio is ranked higher than
67% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PACB: 3.15 )
Ranked among companies with meaningful Quick Ratio only.
PACB' s Quick Ratio Range Over the Past 10 Years
Min: 1.92  Med: 5.33 Max: 22.74
Current: 3.15
1.92
22.74
Days Inventory 104.88
PACB's Days Inventory is ranked lower than
57% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. PACB: 104.88 )
Ranked among companies with meaningful Days Inventory only.
PACB' s Days Inventory Range Over the Past 10 Years
Min: 103.43  Med: 134.83 Max: 196.1
Current: 104.88
103.43
196.1
Days Sales Outstanding 34.45
PACB's Days Sales Outstanding is ranked higher than
82% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. PACB: 34.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
PACB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.52  Med: 35.57 Max: 74.35
Current: 34.45
20.52
74.35
Days Payable 54.22
PACB's Days Payable is ranked lower than
65% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. PACB: 54.22 )
Ranked among companies with meaningful Days Payable only.
PACB' s Days Payable Range Over the Past 10 Years
Min: 28.8  Med: 49.56 Max: 83.1
Current: 54.22
28.8
83.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.80
PACB's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. PACB: -11.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PACB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -380.3  Med: -11.1 Max: 0
Current: -11.8
-380.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.75
PACB's Price-to-Net-Cash is ranked lower than
56% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.00 vs. PACB: 12.75 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PACB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.02  Med: 7.58 Max: 366
Current: 12.75
1.02
366
Price-to-Net-Current-Asset-Value 6.24
PACB's Price-to-Net-Current-Asset-Value is ranked higher than
53% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.01 vs. PACB: 6.24 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PACB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.89  Med: 5.75 Max: 21.54
Current: 6.24
0.89
21.54
Price-to-Tangible-Book 3.52
PACB's Price-to-Tangible-Book is ranked higher than
52% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.57 vs. PACB: 3.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PACB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.8  Med: 4.68 Max: 14.29
Current: 3.52
0.8
14.29
Price-to-Median-PS-Value 0.46
PACB's Price-to-Median-PS-Value is ranked higher than
72% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. PACB: 0.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PACB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42  Med: 0.93 Max: 3.93
Current: 0.46
0.42
3.93
Earnings Yield (Greenblatt) % -30.60
PACB's Earnings Yield (Greenblatt) % is ranked lower than
76% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. PACB: -30.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PACB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3441.4  Med: -20.25 Max: 26741.7
Current: -30.6
-3441.4
26741.7

More Statistics

Revenue (TTM) (Mil) $94.26
EPS (TTM) $ -0.91
Beta2.65
Short Percentage of Float15.96%
52-Week Range $2.66 - 8.00
Shares Outstanding (Mil)116.25

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 90 118 144
EPS ($) -0.73 -0.55 -0.47
EPS without NRI ($) -0.73 -0.55 -0.47
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}